Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial Results
Alnylam Pharmaceuticals (Nasdaq: ALNY) is set to announce financial results for Q4 and the full year ending December 31, 2020, on February 11, 2021. The conference call will occur at 8:30 am ET, discussing performance and future expectations. Investors can access the live audio webcast through their website. Alnylam, founded in 2002, focuses on RNA interference therapeutics, including products like ONPATTRO, GIVLAARI, and OXLUMO. The company’s innovative pipeline aims to address rare and common diseases, underpinned by a robust financial outlook and strategic growth initiatives.
- Strong pipeline with six investigational medicines in late-stage development.
- Established commercial products include ONPATTRO, GIVLAARI, and OXLUMO.
- No financial metrics provided; future guidance remains unclear.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2020 on Thursday, February 11, 2021, before the U.S. financial markets open.
Management will provide an update on the Company and discuss fourth quarter and year-end 2020 results as well as expectations for the future via conference call on Thursday, February 11, 2021 at 8:30 am ET. To access the call, please dial 877-312-7507 (domestic) or +1-631-813-4828 (international) five minutes prior to the start time and refer to conference ID 6180123. A replay of the call will be available beginning at 11:30 am ET on the day of the call. To access the replay, please dial 888-859-2056 (domestic) or +1-404-537-3406 (international) and refer to conference ID 6180123.
A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.
About Alnylam
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran), as well as Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005620/en/
FAQ
When will Alnylam Pharmaceuticals report their Q4 2020 results?
What time is the Alnylam Pharmaceuticals conference call?
How can I access the Alnylam Pharmaceuticals earnings call?
What products does Alnylam Pharmaceuticals currently offer?
What is Alnylam Pharmaceuticals' strategy going forward?
